Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 228.71 USD -0.66% Market Closed
Market Cap: 404.2B USD
Section:
 

Relative Value

The Relative Value of one ABBV stock under the Base Case scenario is 198.9 USD. Compared to the current market price of 228.71 USD, Abbvie Inc is Overvalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBV Relative Value
Base Case
198.9 USD
Overvaluation 13%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.8
P/S
P/S
Price to Sales
6.8
vs History
1
vs Industry
54
Median 3Y
5.6
Median 5Y
4.5
Industry
7.8
Forward
6.5
More Details
172.2
P/E
P/E
Price to Earnings
172.2
vs History
1
vs Industry
2
Median 3Y
59.8
Median 5Y
34.2
Industry
24.4
Forward
21.3
More Details
19.4
P/OCF
P/OCF
Price to OCF
19.4
vs History
12
vs Industry
10
Median 3Y
13.7
Median 5Y
10.6
Industry
21.4
More Details
23.9
P/FCFE
P/FCFE
Price to FCFE
23.9
vs History
12
vs Industry
10
Median 3Y
19.1
Median 5Y
16.8
Industry
23.2
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
0
Median 3Y
20.2
Median 5Y
15.4
Industry
3.3
More Details
7.8
EV/S
EV/S
Enterprise Value to Sales
7.8
vs History
1
vs Industry
42
Median 3Y
6.4
Median 5Y
5.3
Industry
8.4
Forward
7.5
More Details
11
EV/GP
EV/GP
Enterprise Value to Gross Profit
11
vs History
3
vs Industry
37
Median 3Y
9.3
Median 5Y
7.6
Industry
10.3
More Details
16.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.6
vs History
4
vs Industry
8
Median 3Y
13.9
Median 5Y
11.2
Industry
6.5
Forward
16
More Details
23.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.6
vs History
12
vs Industry
6
Median 3Y
21.3
Median 5Y
16.4
Industry
7
Forward
16.8
More Details
22.3
EV/OCF
EV/OCF
Enterprise Value to OCF
22.3
vs History
14
vs Industry
8
Median 3Y
15.7
Median 5Y
13
Industry
7.9
More Details
23.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.6
vs History
14
vs Industry
7
Median 3Y
16.3
Median 5Y
13.4
Industry
6.2
More Details
4.9
EV/IC
EV/IC
Enterprise Value to IC
4.9
vs History
1
vs Industry
32
Median 3Y
3.6
Median 5Y
3
Industry
5.5
More Details

Multiples Across Competitors

ABBV Competitors Multiples
Abbvie Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Abbvie Inc
NYSE:ABBV
404.2B USD 6.8 172.2 16.6 23.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 059 881.3 -161 881.6 -196 575.9 -194 332.7
US
Amgen Inc
NASDAQ:AMGN
183B USD 5.1 26.1 18.7 18.7
US
Gilead Sciences Inc
NASDAQ:GILD
152.3B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 9.9 31.6 23.2 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.4 -527.8 -574.7 -559.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.1B USD 5.3 16.6 15.8 17.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.9B USD 24.8 -191 -478 -328.1
AU
CSL Ltd
ASX:CSL
88.2B AUD 3.8 19.4 13.1 16.3
NL
argenx SE
XBRU:ARGX
48.5B EUR 15.7 36.8 63.9 65.7
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Abbvie Inc
NYSE:ABBV
Average P/S: 3 096 549.7
6.8
9%
0.8
FR
Pharnext SCA
OTC:PNEXF
34 059 881.3
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 068.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
5%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.8
44%
0.6
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.7
46%
0.3
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Abbvie Inc
NYSE:ABBV
Average P/E: 45.9
172.2
89%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 881.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.1
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -191 N/A N/A
AU
CSL Ltd
ASX:CSL
19.4
11%
1.8
NL
argenx SE
XBRU:ARGX
36.8
37%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBITDA: 23.4
16.6
14%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 575.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -478 N/A N/A
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
NL
argenx SE
XBRU:ARGX
63.9
769%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBIT: 25.6
23.6
30%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 332.7 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -328.1 N/A N/A
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
NL
argenx SE
XBRU:ARGX
65.7
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 300,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.